Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Clinigence Holdings ( (NUTX) ) has provided an update.
On September 8, 2025, a derivative action was filed on behalf of Nutex Health Inc. in the U.S. District Court for the Southern District of Texas. The lawsuit names the company’s CEO, CFO, President, and current and former board members as defendants, alleging violations of the Securities Exchange Act, breaches of fiduciary duties, and other misconduct. The action seeks damages, restitution, and corporate governance reforms. Nutex Health is currently unable to predict the litigation’s outcome or its financial impact.
The most recent analyst rating on (NUTX) stock is a Buy with a $300.00 price target. To see the full list of analyst forecasts on Clinigence Holdings stock, see the NUTX Stock Forecast page.
Spark’s Take on NUTX Stock
According to Spark, TipRanks’ AI Analyst, NUTX is a Neutral.
Nutex Health’s overall stock score reflects strong financial performance and attractive valuation, offset by technical weakness and legal risks. The company’s significant revenue growth and profitability are promising, but increased leverage and legal challenges warrant caution.
To see Spark’s full report on NUTX stock, click here.
More about Clinigence Holdings
Average Trading Volume: 252,529
Technical Sentiment Signal: Sell
Current Market Cap: $463.4M
See more data about NUTX stock on TipRanks’ Stock Analysis page.